Banki Haddock Fiora v Glaxo Group Limited

Link copied
Case Copied 31 min read

IP AUSTRALIA

AUSTRALIAN PATENT OFFICE

Banki Haddock Fiora v Glaxo Group Limited [2024] APO 20

Patent:2018282427

Title:COMBINATIONS OF A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2 ADRENORECEPTOR AGONIST

Patentee:Glaxo Group Limited

Opponent:Banki Haddock Fiora

Delegate:Dr S. J. Smith

Decision Date:  28 May 2024

Hearing Date:  28 February 2024, by videoconference

Catchwords:  PATENTS – section 75 – opposition to grant of an extension of term – section 71 – approved form for application for an extension of term – pharmaceutical substance per se an admixture – relevant earliest first regulatory approval date – nature of goods included on the ARTG – opposition unsuccessful – costs awarded

Representation:                   Counsel for the patentee: David Shavin KC

Patent attorney for the patentee: Annabella Newton of Phillips Ormonde Fitzpatrick

Counsel for the opponent: David Larish

Solicitor for the opponent: Banki Haddock Fiora

IP AUSTRALIA

AUSTRALIAN PATENT OFFICE

Patent:2018282427

Title:COMBINATIONS OF A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2 ADRENORECEPTOR AGONIST

Patentee:Glaxo Group Limited

Date of Decision:                28 May 2024

DECISION

The opposition to grant of an extension of term of patent 2018282427 is unsuccessful.  Subject to appeal, I grant the extension of term.

I award costs according to Schedule 8 against Banki Haddock Fiora.

REASONS FOR DECISION

Background

  1. This matter concerns an opposition to an extension of term of patent number 2018282427 (the patent) in the name of Glaxo Group Limited (the patentee).  The patent was granted on 15 July 2021 and the patentee filed an application for an extension of term (the application) of the patent under section 70 of the Patents Act 1990 (the Act) on 3 November 2021.

  2. The application is based on the product TRELEGY ELLIPTA, which was first listed on the Australian Register of Therapeutic Goods (ARTG) on 16 January 2018. Prior to consideration of the application, the patent was re-examined pursuant to section 97 of the Act and the patentee made section 104 amendments to the claims and description which were allowed unopposed on 16 June 2022.  The application was advertised accepted on 7 July 2022.

  3. Banki Haddock Fiora (the opponent) filed a notice of opposition on 7 October 2022 and a statement of grounds and particulars on 23 December 2022. The statement of grounds and particulars identifies the ground as follows: “The Application incorrectly treated the earliest first regulatory approval date as the inclusion of Trelegy Ellipta on the ARTG when the actual earliest first regulatory approval date was the inclusion of Anoro Ellipta on the ARTG.” At the hearing I confirmed with the opponent that this reflected an opposition on the basis that the requirements of section 71 were not satisfied.[1]

    [1] I note that the opponent also observed that the combined effect of sections 76 and 77 is that an extension of zero term could be granted following the opposition.

  4. On 3 January 2023 a delegate of the Commissioner directed that the documents that accompanied the statement of grounds and particulars (various documents concerning the TRELEGY ELLIPTA and ANORO ELLIPTA products and the…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Banki Haddock Fiora v Glaxo Group Limited and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2024] APO 20
Decision Date

CaseChat Overview and Summary

Banki Haddock Fiora (the opponent) opposed the grant of an extension of term of patent number 2018282427 (the patent) in the name of Glaxo Group Limited (the patentee). The patent was granted on 15 July 2021 and the patentee filed an application for an extension of term of the patent under section 70 of the Patents Act 1990 (the Act) on 3 November 2021. The application was based on the product TRELEGY ELLIPTA, which was first listed on the Australian Register of Therapeutic Goods (ARTG) on 16 January 2018. Prior to consideration of the application, the patent was re-examined pursuant to section 97 of the Act and the patentee made section 104 amendments to the claims and description which were allowed unopposed on 16 June 2022. The application was advertised accepted on 7 July 2022. The opponent filed a notice of opposition on 7 October 2022 and a statement of grounds and particulars on 23 December 2022. The opponent argued that the application incorrectly treated the earliest first regulatory approval date as the inclusion of Trelegy Ellipta on the ARTG when the actual earliest first regulatory approval date was the inclusion of Anoro Ellipta on the ARTG. The opponent also argued that the application failed to comply with the requirements of section 71 of the Act because the approved form for making an application for an extension of term required the patentee to indicate the earliest first regulatory approval date, and the application incorrectly identified the earliest first regulatory approval date as the inclusion of Trelegy Ellipta on the ARTG. The court considered the relevant specification for the section 70 analysis, and concluded that the relevant specification was that subsisting at the time of making the decision of compliance with the requirements. The court also considered the nature of the goods included on the ARTG, and concluded that the goods included on the ARTG were limited to the form of the goods as identified in the ARTG – essentially as presented for sale or supply – and not the form of the goods subsequent to supply, for example, at or around the point of administration. The court concluded that the opponent had not established that the application incorrectly identified the earliest first regulatory approval date or, correspondingly, failed to comply with the requirements of section 71. The opposition to the grant of an extension of term was unsuccessful, and costs were awarded according to Schedule 8 against the opponent.

Orders

Orders of the court

Background

Background to the litigation

Evidence

Evidence Before The Court

Decision

Reasons for decision

Ratio Decidendi

Legal Principle Established